Shares of Mersana Therapeutics Inc (NASDAQ:MRSN) have been given a consensus broker rating score of 1.00 (Strong Buy) from the four brokers that provide coverage for the company, Zacks Investment Research reports. Four analysts have rated the stock with a strong buy recommendation.

Brokerages have set a 12-month consensus price target of $23.67 for the company, according to Zacks. Zacks has also given Mersana Therapeutics an industry rank of 101 out of 265 based on the ratings given to its competitors.

Large investors have recently made changes to their positions in the business. California State Teachers Retirement System purchased a new stake in shares of Mersana Therapeutics in the 3rd quarter valued at approximately $142,000. Citadel Advisors LLC purchased a new stake in shares of Mersana Therapeutics in the 2nd quarter valued at approximately $179,000. Bank of New York Mellon Corp purchased a new stake in shares of Mersana Therapeutics in the 3rd quarter valued at approximately $231,000. Goldman Sachs Group Inc. purchased a new stake in shares of Mersana Therapeutics in the 2nd quarter valued at approximately $699,000. Finally, Laurion Capital Management LP purchased a new stake in shares of Mersana Therapeutics in the 2nd quarter valued at approximately $699,000. 76.69% of the stock is currently owned by institutional investors.

Shares of Mersana Therapeutics (NASDAQ:MRSN) opened at $17.98 on Friday. Mersana Therapeutics has a 52 week low of $12.71 and a 52 week high of $21.01.

Mersana Therapeutics (NASDAQ:MRSN) last announced its earnings results on Thursday, November 9th. The company reported ($0.35) earnings per share for the quarter, topping the consensus estimate of ($0.48) by $0.13. Mersana Therapeutics had a negative net margin of 123.38% and a negative return on equity of 517.44%. The firm had revenue of $6.27 million for the quarter, compared to the consensus estimate of $3.93 million. equities analysts anticipate that Mersana Therapeutics will post -2.9 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This piece of content was posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this piece of content on another publication, it was stolen and republished in violation of US & international copyright & trademark law. The original version of this piece of content can be viewed at https://theolympiareport.com/2017/12/15/zacks-brokerages-set-23-67-price-target-for-mersana-therapeutics-inc-mrsn.html.

Mersana Therapeutics Company Profile

Mersana Therapeutics, Inc is a United States-based biotechnology company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs). The Company focuses on advancing a pipeline of targeted oncology therapeutics leveraging its Fleximer immunoconjugate technology. The Fleximer platform allows it to design ADCs with specific properties and manage the drug’s chances of attacking cancers.

Get a free copy of the Zacks research report on Mersana Therapeutics (MRSN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with Analyst Ratings Network's FREE daily email newsletter.